Table 7.
Risk factors of clinically significant complications in patients with asymptomatic lesions
| Variables | OR [95% CI] | P-value |
|---|---|---|
| Age, per year increment | 1.04 [0.99–1.10] | 0.14 |
| Male sex | 0.99 [0.37–2.64] | 0.98 |
| Acute intervention (within 14 days) | 1.44 [0.55–3.74] | 0.47 |
| Degree of stenosis, per percentage increment | 0.99 [0.97–1.03] | 0.74 |
| High-intensity signal on TOF MRA | 1.51 [0.69–3.28] | 0.31 |
| Dual/Triple antiplatelet therapy | 1.74 [0.20–15.2] | 0.61 |
| Aspirin | 0.60 [0.10–3.51] | 0.57 |
| Ticlopidine/Clopidogrel | 0.34 [0.06–1.80] | 0.19 |
| Cilostazole | 0.42 [0.09–2.01] | 0.24 |
| EPD use | – | – |
| Distal filter protection | 1.60 [0.63–4.12] | 0.32 |
| Proximal/combined protection | 2.54 [0.89–7.23] | 0.08 |
| MoMa | 2.52 [0.88–7.18] | 0.1 |
| Pre-dilatation | 0.75 [0.20–2.77] | 0.68 |
| Post-dilatation | 0.71 [0.21–2.42] | 0.6 |
| Closed-cell stent | 0.63 [0.29–1.38] | 0.24 |
Analysis based on data from the Japanese Registry of NeuroEndovascular Therapy 3 (JR-NET3). CAS: carotid artery stenting, CI: confidence interval, EPD: embolic protection device, MoMa: Mo.Ma Ultra (Medtronic, Minneapolis, MN, USA), OR: odds ratio, SD: standard deviation, TOF MRA: time-of-flight magnetic resonance angiography.